ArticleBMC infectious diseases2026
Assessing the global burden of acute viral hepatitis in the elderly: a comprehensive analysis of data from the GBD 2021 database.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDespite advances in prevention and treatment, the burden of acute viral hepatitis (AVH) remains substantial yet understudied in the elderly. In this study, we used data from the Global Burden of Disease (GBD) 2021 database to analyze burden, inequality, and trends associated with acute hepatitis from 1990 to 2021 in individuals aged 60 years and above.
methodsData on AVH burden in the elderly were extracted from the GBD 2021 database for analysis of age-standardized prevalence rates (ASPR), age-standardized incidence rates(ASIR), age-standardized mortality rates(ASMR), age-standardized disability-adjusted life years [DALYs] rates(ASDR) and demographic factors (gender, age group). Analytical techniques included joinpoint regression, decomposition analyses, and predictive modeling to assess temporal trends and future projections.
resultsFrom 1990 to 2021, trends in global age-specific prevalence, incidence, mortality, and DALY rates (ASPR, ASIR, ASMR, and ASDR, respectively) were consistently downward. Specifically, low–Social Development Index (SDI) countries exhibited higher prevalence, incidence, and mortality rates and more DALYs. Frontier analysis showed that the AVH-related ASDR from 1990 to 2021 generally decreased with increasing SDI, indicating that higher levels of social development were associated with better health outcomes in the elderly. Generally, age analysis indicated declines in prevalence and incidence with age, with a valley around 85–89 years for most SDI regions, followed by a slight rise. By 2050, ASPR and ASIR were projected to show an upward trend, while ASMR and ASDR were expected to decline.
conclusionsThis study highlighted a continuing, albeit declining, burden of AVH in the elderly, with stark regional disparities influenced by sociodemographic factors. Despite reductions in incidence and prevalence, mortality and DALYs remain high in low-SDI regions, underscoring the need for targeted interventions. These findings stress the importance of equitable healthcare strategies to address the specific needs of the elderly population worldwide and help achieve the hepatitis elimination goals of the World Health Organization. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.